Revolution Medicines (NASDAQ:RVMD) CFO Sells $273,868.44 in Stock

Revolution Medicines, Inc. (NASDAQ:RVMD) CFO Jack Anders sold 2,753 shares of the stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total transaction of $273,868.44. Following the transaction, the chief financial officer owned 125,512 shares in the company, valued at $12,485,933.76. This trade represents a 2.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Jack Anders also recently made the following trade(s):

• On Wednesday, January 7th, Jack Anders sold 10,000 shares of Revolution Medicines stock. The stock was sold at an average price of $98.00, for a total transaction of $980,000.00.

Revolution Medicines Stock Performance

Shares of Revolution Medicines stock opened at $95.78 on Friday. The firm has a market cap of $18.98 billion, a PE ratio of -16.21 and a beta of 0.99. The firm’s 50-day simple moving average is $102.96 and its 200-day simple moving average is $77.07. The company has a debt-to-equity ratio of 0.16, a quick ratio of 7.14 and a current ratio of 7.14. Revolution Medicines, Inc. has a 1 year low of $29.17 and a 1 year high of $124.49.

Revolution Medicines (NASDAQ:RVMD) last posted its quarterly earnings results on Wednesday, February 25th. The company reported ($1.86) EPS for the quarter, missing analysts’ consensus estimates of ($1.56) by ($0.30). During the same period last year, the business posted ($1.12) earnings per share. Equities analysts forecast that Revolution Medicines, Inc. will post -3.49 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Revolution Medicines

Several institutional investors have recently made changes to their positions in the stock. Global Retirement Partners LLC raised its position in shares of Revolution Medicines by 1,002.8% during the 4th quarter. Global Retirement Partners LLC now owns 397 shares of the company’s stock worth $32,000 after purchasing an additional 361 shares during the period. Indiana Trust & Investment Management Co acquired a new position in Revolution Medicines during the 4th quarter valued at approximately $32,000. Torren Management LLC acquired a new position in Revolution Medicines during the 4th quarter valued at approximately $33,000. Arax Advisory Partners bought a new position in Revolution Medicines during the 4th quarter worth $38,000. Finally, Darwin Wealth Management LLC bought a new position in Revolution Medicines during the 4th quarter worth $40,000. 94.34% of the stock is owned by institutional investors.

Revolution Medicines News Roundup

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Large institutional interest — several big funds (General Atlantic, Norges Bank, Avoro, UBS, Polar Capital) have taken or increased stakes recently, which signals strong institutional conviction and can provide buying support. MarketBeat Institutional/Insider Summary
• Positive Sentiment: Analyst tone is largely favorable — multiple upgrades/initiations and a consensus “Buy” bias underpin positive sentiment among investors and can stabilize demand. Analyst Coverage Summary
• Neutral Sentiment: Company profile and pipeline are long-term positives but carry standard biotech clinical/readout risk — lead programs include RMC‑4630 (SHP2), RMC‑6291 (KRAS G12C) and RMC‑6236 (pan‑RAS).
• Neutral Sentiment: Recent results (Feb. 25) showed a wider-than-expected quarterly loss (EPS -$1.86 vs. -$1.56 est.), a reminder of ongoing cash burn and negative EPS guidance for the year — a typical headwind for development-stage biotechs. Earnings Summary
• Negative Sentiment: Unusual options activity — investors bought 12,797 put contracts (a ~131% increase vs. average put volume of 5,546), a bearish flow that can amplify near‑term downside and volatility.
• Negative Sentiment: Cluster of insider sales on Mar. 17 — several senior insiders trimmed positions (Mark A. Goldsmith 12,871 shares; Margaret A. Horn 4,583; Stephen M. Kelsey 4,302; Jack Anders 2,753; Lin Wei 2,073; Xiaolin Wang 2,010). Multiple Form 4 filings were submitted to the SEC, which can be interpreted negatively by some investors even if sales are for diversification or routine reasons. SEC filings: Read More. · Read More. · Read More. · Read More. · Read More. · Read More.

Analyst Ratings Changes

RVMD has been the subject of several research reports. Benchmark reiterated an “overweight” rating on shares of Revolution Medicines in a research report on Tuesday, February 17th. UBS Group assumed coverage on Revolution Medicines in a research report on Friday, February 27th. They set a “buy” rating on the stock. Wedbush restated an “outperform” rating on shares of Revolution Medicines in a research note on Friday, January 9th. Jefferies Financial Group initiated coverage on shares of Revolution Medicines in a report on Monday, March 16th. They issued a “buy” rating for the company. Finally, Evercore upgraded shares of Revolution Medicines to a “strong-buy” rating in a research note on Wednesday, February 25th. Four research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $78.94.

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.